Articles by Jill Wechsler - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Jill Wechsler

Jill Wechsler

Washington Editor

Jill Wechsler is Pharmaceutical Technology's Washington editor. She can be contacted by postal mail at 7715 Rocton Ave., Chevy Chase, MD 20815, by telephone at 301.656.4634, or by e-mail at jillwechsler7@gmail.com.

Articles
Biopharma Manufacturers Respond to Ebola Crisis
October 2, 2014

Demand for new therapies and vaccines spotlights production challenges.

Data Integrity Key to GMP Compliance
September 2, 2014

FDA demands accurate manufacturing and test information to ensure product quality.

FDA Strategies Designed to Speed Generic Drug Approvals
September 1, 2014

A surge in generic drug applications is testing FDA?s ability to reduce the backlog of ANDAs.

Changes and Challenges for Generic Drugs
August 2, 2014

FDA seeks high quality applications and products to facilitate approvals and reduce safety and supply problems.

Industry Seeks Clearer Standards for Track and Trace
July 2, 2014

Stakeholders face challenges and benefits from a more secure pharmaceutical supply chain.

Globalization Challenges Drug Regulators
June 29, 2014

Regulators and industry organizations explain policies and standards to manufacturers and authorities across the globe.

Global Expansion Shapes Drug Oversight
June 2, 2014

Regulators and industry organizations explain policies and standards to manufacturers and authorities in all regions.

Demand for New Vaccines Spurs Innovation
May 2, 2014

New formulations and expanded vaccine production are encouraged.

FDA and Industry Take Action for a More Secure Drug Supply Chain
May 2, 2014

New identifiers and tracking requirements aim to block illegitimate products.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
43%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FindPharma Custom Search
Click here